NIH honors chemist for innovative
work on antibodies
David Spiegel, assistant professor of organic chemistry, has received a $1.5
million National Institutes of Health (NIH) Director’s New Innovator
Award that will support his work designing a “rational” approach
for using antibodies to target a wide variety of cells and disease types.
The New Innovator Awards are reserved for investigators of exceptional promise,
who are just beginning their careers and have not yet received a regular research
grant from the NIH.
“New investigators are the future of science, and innovative ideas are
its lifeblood,” says Dr. Elias Zerhouni, NIH director. “The creative
scientists we recognize are well-positioned to make significant and potentially
transformative discoveries in a variety of areas.”
The NIH award will fund Spiegel’s project titled “Small-Molecule
Antibody Recruiting Therapeutics for Treating Human Disease,” in
which he is exploring a novel approach to using antibodies that recognize a
single small molecule as a universal agent for targeting and destroying many
different pathogens and various types of diseased cells.
For many years, physicians and scientists have used the common small molecule
dinitrophenyl (DNP) chloride in immunizations in order to generate anti-DNP antibodies
as a test of the status of the immune system. Spiegel is now coupling DNP with
agents that recognize pathogens like HIV or surface elements of specific cell
types. He theorizes that when cells, bacteria or viruses are exposed to these
compounds, they will effectively become “coated” with DNP, attract
the anti-DNP antibodies and then be destroyed.
“Scientists have found that for no apparent reason, about 20% of people
already have DNP antibodies in their system, and it is easy and harmless to induce
DNP-antibody production,” says Spiegel. “Our task will be to rationally
design DNP-compounds that recognize pathogens and act as ‘magnets’ for
the antibody.
“Rational design is the key and the advantage to this approach,” Spiegel
adds. “Rather than using the brute force approach of screening combinatorial
libraries of synthetic compounds, we already have cell-specific and pathogen-specific
targeting molecules we can use or modify.”
As a synthetic chemist, Spiegel will identify the best pathogen-targeting molecules
and the best way of arranging them in relationship to DNP in order to attract
DNP-antibodies to the constructed compound. As a physician, his aim is to redirect
the immune system to deal as simply as possible with multiple “diseases.”
The five-year grant to Spiegel was among the first group of Innovator Awards
in the NIH Roadmap for Medical Research Initiative that tests new approaches
to supporting research. Awards were made to 30 researchers out of 2,200 applicants,
of these, only three of the awardees, including Spiegel, are in chemistry departments.
Yale cell biologist Derek Toomre also received one of the awards for his innovative
work on microscopes. (See the Sept. 28 issue of the Yale Bulletin & Calendar.)
“David Spiegel possesses a stunning and eclectic background that has set
the stage for an exciting career in academic science,” says Gary Brudvig,
professor and chair of chemistry. “His training in chemistry and medicine
combine to bring great promise to this new area of therapeutics. We are delighted
that his creativity and potential as an outstanding investigator has been acknowledged
through this NIH award.”
Spiegel earned his undergraduate degree with highest honors at Harvard University.
He matriculated at Yale in the M.D./Ph.D. program, and due to his great interest in chemistry completed the Ph.D.
portion of his program pursuing projects in organic synthesis in the laboratory
of Yale chemist John Wood. After his postdoctoral training with Stuart L. Schreiber
at Harvard, Spiegel joined the Yale faculty in the Department of Chemistry in
July 2007.
The NIH Roadmap for Medical Research is a series of far-reaching initiatives
designed to transform the nation’s medical research capabilities. The conceptual
and technological breakthroughs likely to emerge from these highly innovative
approaches to major research challenges are expected to speed progress toward
important medical advances.
— By Janet Rettig Emanuel
T H I S
W E E K ' S
S T O R I E S

Alumnus makes major gift to new cancer care facility


New Yale ALERT system to allow instant communications . . .


Microsoft-Yale project will provide worldwide access to . . .


NIH honors chemist for innovative work on antibodies


NIH-funded study to explore how damaged cancer cells mend


Study: New brain cells listen before they talk


Study shows tiny RNAs play big role in controlling genes


Yale geologist honored for research on climate variations


New Yale opera group will debut with a performance of . . .


Yale singing groups come together for a concert to benefit United Way


‘The Future of Energy’ conference to assess issues of next 25 years


Ten Yale scientists are honored with election as fellows of the AAAS


Funding cuts have created a ‘crisis’ in the battle against cancer, says panel


OCR chief testifies before Congress


Memorial service for Kitty Lustman-Findling to be held on Nov. 10


Frederick Douglass Prize awarded for book exploring . . .


Autumn’s paintbrush


Yale Books in Brief


Campus Notes

Bulletin Home
|
Visiting on Campus
|
Calendar of Events
|
In the News

Bulletin Board
|
Classified Ads
|
Search Archives
|
Deadlines

Bulletin Staff
|
Public Affairs
|
News Releases
|
E-Mail Us
|
Yale Home